Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Authors	PROETEL U ŽÁČKOVÁ Daniela PLETSCH N LAUSEKER M MULLER M C HANFSTEIN B KRAUSE SW KALMANTI L SCHREIBER A HEIM D BAERLOCHER GM HOFMANN WK LANGE E EINSELE H WERNLI M KREMERS S SCHLAG R MULLER L HANEL M LINK H HERTENSTEIN B PFIRRMANN M HOCHHAUS A HASFORD J HEHLMANN R SAUSSELE S
Year of publication	2014
Type	Article in Periodical
Magazine / Source	Annals of hematology
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1007/s00277-014-2041-0
Keywords	Chronic myeloid leukemia; Older patients; Different imatinib dose regimens; Early applied higher imatinib dosages
Description	The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (a parts per thousand yen65 years vs. < 65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were a parts per thousand yen65 years. The median dose per day was lower for patients a parts per thousand yen65 years on IM800, with the highest median dose in the first year (466 mg/day for patients a parts per thousand yen65 years vs. 630 mg/day for patients < 65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874.